news
Hims plans testosterone replacement therapy rollout for men
Telehealth giant Hims & Hers announced plans to enter testosterone replacement therapy, marking its first move into prescribing Schedule III controlled substances. The service pairs at-home blood panels with clinician consultations to target men struggling with low energy and declining hormone baselines. It signals a major land grab in an aggressive direct-to-consumer men's endocrine market.
Telehealth giant Hims & Hers announced plans to enter testosterone replacement therapy, marking its first move into prescribing Schedule III controlled substances. The service pairs at-home blood panels with clinician consultations to target men struggling with low energy and declining hormone baselines. It signals a major land grab in an aggressive direct-to-consumer men's endocrine market.
The architecture take
Telehealth sold convenience for hair loss and ED, but moving into Schedule III testosterone puts an endocrine sledgehammer into the mail. Testosterone therapy shuts down your body's own luteinizing hormone and FSH signaling through the pituitary loop. Once you take exogenous T, your testes stop producing their own, which means testicular shrinkage and a long-term commitment unless you want to endure a brutal crash. I used to think direct-to-consumer diagnostics would push guys to fix their sleep and insulin sensitivity before touching a needle. I was wrong. The financial incentive here is keeping subscribers anchored to a recurring monthly vial, not sorting out the four hours of fragmented sleep and elevated cortisol that cratered their morning free testosterone in the first place. If you give a 28-year-old an online questionnaire and a mailed vial without an ultrasound or a pituitary workup, you are managing a symptom while suppressing a feedback loop. Watch the DEA step in next.